D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - AVNT Nov Investor Meetings Update AVIENT CORPORATION I N V E S TO R M E E T I N G S (NYSE: AVNT) N OV E M B E R 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of November 8, 2021 86 93 85 83 79 77 75 89 85 83 81 79 79 78 77 74 25 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E B N R H X L A S H E C L E M N H U N S C L A L B (10) Source: Peer data per Bloomberg market data as of November 8, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below many of our specialty formulator peers. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 33 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.4 20.2 16.7 16.5 14.7 12.0 10.8 40.7 29.9 26.2 13.2 12.4 11.0 10.9 9.1 9.0 7.5 6.5 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - Avient IR Presentation - May 2021 AVIENT CORPORATION M AY 2 0 2 1 I N V E S T O R M E E T I N G S (NYSE: AVNT) DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 28 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - Avient February IR Meetings AVIENT CORPORATION (NYSE: AVNT) F E B R U A R Y 1 7 - 1 8 , 2 0 2 1 I N V E S T O R M E E T I N G S H O S T E D B Y G O L D M A N S A C H S A N D M O R G A N S T A N L E Y DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 27 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?

STAN-TONE HCC- M-RED STAN-TONE HCC- M-61 GRAY STAN-TONE MB- WHITE

This is a direct result of the investments we have made to transform our portfolio to one that is more specialized and focused on high growth end markets with sustainable solutions,” said Robert M. Reconciliation of Pro Forma Adjusted Earnings per Share: Three Months Ended March 31, 2020 Net income from continuing operations attributable to Avient shareholders $ 33.1 Special items, after tax (Attachment 3) 8.6 Adjusted net income from continuing operations excluding special items 41.7 Clariant MB pro forma adjustments to net income from continuing operations(2) 7.8 Pro forma adjusted net income from continuing operations attributable to Avient shareholders $ 49.5 Weighted average diluted shares 86.7 Pro forma impact to diluted shares from January 2020 equity offering 6.1 Pro forma weighted average diluted shares 92.8 Adjusted EPS - excluding special items pro forma for Clariant MB acquisition $ 0.53 Year Ended December 31, 2020 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(2) Pro Forma Adjusted Avient Sales $ 3,242.1 $ — $ 3,242.1 $ 540.4 $ 3,782.5 Operating income $ 189.3 $ 73.7 $ 263.0 $ 45.0 $ 308.0 Interest expense, net (74.6) 10.1 (64.5) (18.1) (82.6) Other income, net 24.3 (17.6) 6.7 — 6.7 Income taxes (5.2) (41.4) (46.6) (6.2) (52.8) Net income attributable to noncontrolling interests (1.8) — (1.8) — (1.8) Net income from continuing operations attributable to Avient shareholders $ 132.0 $ 24.8 $ 156.8 $ 20.7 $ 177.5 Weighted average diluted shares 90.6 Impact to diluted shares from January 2020 equity offering 1.5 Pro forma weighted average diluted shares 92.1 Pro forma adjusted EPS $ 1.93 (2) Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects to the financing for the acquisition 14 Year Ended December 31, 2019 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(3) Pro Forma Adjusted Avient Sales $ 2,862.7 $ — $ 2,862.7 $ 1,118.6 $ 3,981.3 Operating income $ 156.8 $ 71.7 $ 228.5 $ 72.9 $ 301.4 Interest expense, net (59.5) — (59.5) (33.4) (92.9) Other income, net 12.1 (10.0) 2.1 — 2.1 Income taxes (33.7) (5.9) (39.6) (9.1) (48.7) Net income attributable to noncontrolling interests (0.2) — (0.2) — (0.2) Net income from continuing operations attributable to Avient shareholders $ 75.5 $ 55.8 $ 131.3 $ 30.4 $ 161.7 Weighted average diluted shares 77.7 Impact to diluted shares from January 2020 equity offering 15.3 Pro forma weighted average diluted shares 93.0 Pro forma adjusted EPS $ 1.74 (3) Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects to the financing for the acquisition 15 Reconciliation of EBITDA by Segment Three Months Ended March 31, Year Ended December 31, 2021 2020 2020 2019 2018 Operating income: Color, Additives and Inks $ 88.8 $ 40.5 $ 180.8 $ 147.4 $ 158.5 Specialty Engineered Materials 34.2 22.3 94.4 83.7 72.3 Distribution 24.0 19.4 69.5 75.4 71.5 Corporate and eliminations (26.6) (29.4) (155.4) (149.7) (123.7) Operating income $ 120.4 $ 52.8 $ 189.3 $ 156.8 $ 178.6 Items Below OI in Corporate Other income, net $ 1.5 $ 1.6 $ 24.3 $ 12.1 $ (12.9) Depreciation & Amortization: Color, Additives and Inks $ 27.4 $ 10.9 $ 75.1 $ 42.7 $ 44.3 Specialty Engineered Materials 7.8 7.5 30.0 29.5 23.2 Distribution 0.2 0.1 0.7 0.5 0.7 Corporate and eliminations 1.7 1.4 9.2 5.4 4.4 Depreciation & Amortization $ 37.1 $ 19.9 $ 115.0 $ 78.1 $ 72.6 EBITDA Color, Additives and Inks $ 116.2 $ 51.4 $ 255.9 $ 190.1 $ 202.8 Specialty Engineered Materials 42.0 29.8 124.4 113.2 95.5 Distribution 24.2 19.5 70.2 75.9 72.2 Corporate and eliminations (24.9) (28.0) (146.2) (144.3) (119.3) EBITDA $ 159.0 $ 74.3 $ 328.6 $ 247.0 $ 238.3 EBITDA as a % of Sales: Color, Additives and Inks 19.1 % 20.0 % 17.0 % 18.9 % 19.4 % Specialty Engineered Materials 19.4 % 16.1 % 17.6 % 15.2 % 14.8 % Distribution 6.7 % 6.7 % 6.3 % 6.4 % 5.7 % 16 Reconciliation of Pro Forma EBITDA - Color, Additives and Inks Three Months Ended March 31, Year Ended December 31, 2020 2020 2019 2018 Sales: Color, Additives and Inks $ 256.5 $ 1,502.9 $ 1,003.8 $ 1,046.5 Clariant MB pro forma adjustments(4) 279.4 540.4 1,118.6 1,209.8 Pro forma sales $ 535.9 $ 2,043.3 $ 2,122.4 $ 2,256.3 Operating income: Color, Additives and Inks $ 40.5 $ 180.8 $ 147.4 $ 158.5 Clariant MB pro forma adjustments(4) 23.0 45.0 72.9 80.3 Pro forma operating income $ 63.5 $ 225.8 $ 220.3 $ 238.8 Depreciation & amortization: Color, Additives and Inks $ 10.9 $ 75.1 $ 42.7 $ 44.3 Clariant MB pro forma adjustments(4) 15.1 30.1 60.3 61.2 Pro forma depreciation & amortization $ 26.0 $ 105.2 $ 103.0 $ 105.5 Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Color, Additives and Inks $ 51.4 $ 255.9 $ 190.1 $ 202.8 Clariant MB pro forma adjustments(4) 38.1 75.1 133.2 141.5 Pro forma EBITDA $ 89.5 $ 331.0 $ 323.3 $ 344.3 Pro forma EBITDA as a % of Sales 16.7 % 16.2 % 15.2 % 15.3 % Three Months Ended March 31, Year Ended December 31, Reconciliation to Adjusted EBITDA: 2021 2020 2020 2019 2018 Net income from continuing operations – GAAP $ 79.7 $ 33.1 $ 133.8 $ 75.7 $ 87.4 Income tax expense 22.9 11.9 5.2 33.7 14.4 Interest expense 19.3 9.4 74.6 59.5 62.8 Debt extinguishment cost — — 1.1 Depreciation and amortization from continuing operations 37.1 19.9 115.0 78.1 72.6 EBITDA $ 159.0 $ 74.3 $ 328.6 $ 247.0 $ 238.3 Special items, before tax 2.4 9.6 66.2 61.7 59.5 Interest expense included in special items — — (10.1) — — Accelerated depreciation included in special items (0.5) — (3.2) — (3.0) Adjusted EBITDA $ 160.9 $ 83.9 $ 381.6 $ 308.7 $ 294.8 Reconciliation of Pro Forma Sales: Three Months Ended March 31, 2020 Sales $ 711.5 Clariant MB pro forma adjustment to sales(4) 279.4 Pro forma sales $ 990.9 (4) Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) 17 Avient Announces Record First Quarter 2021 Results; Increases Full Year Guidance.pdf NEWS RELEASE 4.29 232pm News Release (002).pdf

STAN-TONE MB-31134 GOLD RUSH STAN-TONE MB-31063 BURNT UMBER STAN-TONE MB-31022 PEARL

STAN-TONE MB-103298 PEARL RED 9505 STAN-TONE MB-103303 PEARL RED 504 STAN-TONE MB-27854 GREEN

POLYMER PRODUCT NAME PROPERTY PERFORMANCE TYPE DOSAGE/ LDR MATERIAL CODE ABS FRABS92991 UL 94 Halogen 35% CC10292991WE ABS FRABS52399 UL 94 Halogen 5–14% CC10252399WE HDPE Cesa Flam MB 5101AH UL 94 Halogen 7–16% PEAN698479 Nylon Cesa Flam MB 5728H UL 94 Halogen 8–14% ABA0698450 Nylon Cesa Flam MB 5731NH UL 94 Non-halogen 8–20% ABAN698410 PC Cesa Flam NCA0820018NH UL 94 Non-halogen 2–4% NCA0820018 PC NCAN-Z0N-FN FLMRET 698419 UL 94 Non-halogen 3–8% NCAN698419 PE FRPE94802 ASTM E84 Non-halogen 100% CC103094802F PE FRPE41011 UL 94 Halogen 20–30% CC1034101160 PET Cesa Flam MB 5525NH UL 1441, UL 94 Non-halogen 6–8% NEAN698534 PET FRPET65462 UL 94 Non-halogen 5–12% CC103265462F PET/PBT Cesa Flam MB 5532NH NFPA 701 Non-halogen 4–6% NBAN698451 PP Cesa Flam MB 5201H UL 94 Halogen 6–30% PPAN698410 PP Cesa Flam MB CT-1629NH Cal TB 133, UL 94 Film, NFPA 701 Non-halogen 6–8% PPAN698428 PP FRPP365370 UL 94 Non-halogen 10–20% CC103653702F PP Copolymer FRPP37654 UL 94 5VA Halogen 100% CC10337654WE PP Copolymer FRPP53484 UL 94 Halogen 10% CC1035348460 PS FRPS62722 ASTM E84 Halogen 2–4% CC10262722WE PS/HIPS Cesa Flam SLA0820014H UL 94 Halogen 4–8% SLA0820014H TPU Cesa Flam 98461NH UL 94 Non-halogen 6–14% RUA0698461 CESA™ MAX FLAME RETARDANT ADDITIVES HDPE Cesa MAX UL 94 Non-halogen 20–30% CC10277471 PE/PP Cesa MAX UL 94 Non-halogen 5–35% CC10407512WE

This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner. 1.844.4AVIENT www.avient.com System Syncure XLPE S200FH Syncure XLPE S200FV Applications Building Wire, Tray Cable, Service Entrance Building Wire, Tray Cable, Service Entrance Specification UL 44 UL 44 Wire Type RHW-2, RHW, RHH, XHHW-2, XHH, XHHW, SIS RHW, RHH, RHW-2 Components 78% S1054A 22% SC5400-0002 RoHS MB ALT FR 50% S1054A 50% SC5400-0003 RoHS MB ALT FR Features Horizontal Flame, DBDPE-free VW-1, DBDPE-free General Properties Specific Gravity (g/cm3) 1.01 1.31 Hardness Shore D, 10sec 47 48 Gel % 68 70 Tensile Properties Tensile Strength (psi) 2800 3200 Elongation % 400 470 Tensile Retention % 95 100 Elongation Retention % 90 93 Electrical Dielectric Strength (V/mil) 1000 1200 Dielectric Constant 2.31 2.61 Dissipation Factor % 0.0012 0.0043 Thermal Temperature Rating °C 90 90 Heat Deformation % 10 5 TECHNICAL PROPERTIES